Table 1 Baseline characteristics of patients in the INPULSIS and INSTAGE trials
From: Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
INPULSIS | INSTAGE | ||
|---|---|---|---|
Nintedanib (n = 638) | Placebo (n = 423) | Nintedanib (n = 136) | |
Age, years, mean (SD) | 66.6 (8.1) | 67.0 (7.9) | 70.0 (7.9) |
Male, n (%) | 507 (79.5) | 334 (79.0) | 106 (77.9) |
Body mass index, kg/m2 | 28.1 (4.6) | 27.6 (4.6) | 26.5 (4.7) |
Race, n (%) | |||
White | 360 (56.4) | 248 (58.6) | 95 (69.9) |
Asian | 194 (30.4) | 128 (30.3) | 39 (28.7) |
Othera | 84 (13.2) | 47 (11.1) | 2 (1.5) |
Time since diagnosis of IPF, years, mean (SD) | 1.7 (1.4) | 1.6 (1.3) | 2.1 (1.8) |
FVC, % predicted, mean (SD) | 79.7 (17.6) | 79.3 (18.2) | 66.1 (18.7) |
FEV1/FVC ratio, %, mean (SD) | 81.7 (5.8) | 81.7 (6.0) | 83.8 (7.6) |
DLco, % predicted, mean (SD)b | 47.4 (13.5) | 47.0 (13.4) | 25.6 (7.0) |
SGRQ total score, mean (SD)c | 39.5 (19.2) | 39.6 (18.5) | 54.0 (17.9) |